OncoLab plans to expand its business scope based on the diverse applicability of ANGel platform, developing treatments not only for triple-negative breast cancer but also for various diseases such as other solid tumors, immune disorders, and inflammatory diseases.
Research and Development Pipeline
- ANGel-TNBC01,02
PD-1:PD-L1:CTLA4
- TNBC
-
ANGel optimization
& payload confirmed
- In vitro & Preclinical efficacy,
MOA, toxicity completed
- GLP-level efficacy, viability,
MOA, toxicity,Humanized mouse efficacy
- IND sub., in-house phase 1 pre & IRB,
Investigator-led phase 1
-
Open innovation
platform
out-licensing
(’27)
- Global phase 1 entryDomestic phase 1 efficacy
- ANGel-PSC01,02
- Pancreatic
Cancer
-
ANGel opt, payload set;
Cell tests done
- Preclinical efficacy, viability, MOA, toxicity
- GLP-level efficacy, viability, MOA, toxicityHumanized mouse efficacy
- Oncology pivot, Phase 1 prep
- ANGel-SM0X
- Sclerosing
cholangitis
(JR)
-
ANGel SM loading & Process set
- In vitro & Preclinical efficacy, MOA, toxicity completed
- Preclinical efficacy, viability, MOA, toxicityHumanized mouse efficacy
- Modality pivot, Phase 1 prep
- ANGel-PEP0X
- Obesity
Diabetes
(JR)
-
ANGel Peptide loading & Process set
- Cell-level efficacy & toxicity
- Preclinical efficacy, viability, MOA, toxicity
- Modality pivot, Phase 1 prep
Clinical Status
and Future Plans for Triple-Negative Breast Cancer
and Prostate Cancer Treatments
-
ANGel-TNBC01 (Triple-Negative Breast Cancer Treatment)
This is the first pipeline developed based on ANGel platform. Preclinical studies are currently complete, and we aim to enter Phase 1 clinical trials in Q4 2026.
-
ANGel-TNBC02 (Triple-Negative Breast Cancer Treatment)
This pipeline aims to maximize cancer treatment efficacy and broaden its applicability by obtaining additional clinical data from ANGel-TNBC01. We target Phase 1 clinical trials in Q4 2027.
-
ANGel-PSC01 (Prostate Cancer Treatment)
Based on the experience gained from developing treatments for triple-negative breast cancer, we are conducting research for developing prostate cancer treatment. We aim to enter Phase 1 clinical trials in Q4 2028.
-
ANGel-PSC02 (Prostate Cancer Treatment)
This pipeline aims to maximize cancer treatment efficacy and expand its applicability by obtaining additional clinical data from ANGel-PSC01. We target Phase 1 clinical trials in Q4 2029.